Canada
· Delayed Price · Currency is CAD RepliCel Life Sciences Company Description
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits.
Its treatments use autologous cell therapy to treat tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons.
The company’s product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy foraging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration.
It is also developing DermaPrecise, a dermal injection device. The company has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01, RCT-01, and DermaPrecise.
RepliCel Life Sciences Inc. is based in Vancouver, Canada.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Andrew Schutte |
Contact Details
Address: 570 Granville Street Vancouver, British Columbia V6C 3P1 Canada | |
| Phone | 604 248 8730 |
| Website | replicel.com |
Stock Details
| Ticker Symbol | RP |
| Exchange | TSX Venture Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA76027P4006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Andrew Schutte | President, Chief Executive Officer and Director |
| Dr. Kevin John McElwee Ph.D. | Co-Founder and Chief Scientific Officer |
| David Kwok CPA | Chief Financial Officer |
| Ben Austring | Chief Legal Officer, Corporate Secretary and Chief Operating Officer |